As vaccine technology advances, more specialized immunigens that offer better protection against new or evolving diseases are being created, as evidenced by the diversity of SARS-COV-2 vaccines.  But these vaccines often lack the inherent triggering power of live or inactivated pathogens.

Adjuvants stimulate stronger and longer-lasting immune reactions, improving vaccine effectiveness. They are especially helpful for elderly, immunocompromised and pediatric patients who do not generate effective responses to vaccines.

Until recently, few adjuvants were available for clinical trials and use in humans. However, with changes in the intellectual property landscape, there is a renewed opportunity for companies to specialize in adjuvant development and supply to vaccine developers.